Acceleron Earns $7 Million Milestone Payment for Celgene's Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis

Acceleron Earns $7 Million Milestone Payment for Celgene's Initiation of Sotatercept Phase 2 Clinical Trial in Patients with End Stage Renal Disease on Hemodialysis

December 18, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene, has initiated a phase 2 clinical trial of sotatercept in patients with end stage renal disease on hemodialysis.

Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors

Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors

December 17, 2013

CAMBRIDGE, Mass./PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics(TM), a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Theo Melas-Kyriazi, CFO of Levitronix Technologies LLC and a director of Valeant Pharmaceuticals International (NYSE: VRX and TSX: VRX) has joined Moderna's board of directors.

Dr. Nathanael Gray, a Syros Pharmaceuticals Scientific Founder, Honored with 2013 Meyenburg Cancer Research Award

Dr. Nathanael Gray, a Syros Pharmaceuticals Scientific Founder, Honored with 2013 Meyenburg Cancer Research Award

December 16, 2013

Dr. Gray recognized for developing first-in-class protein kinase inhibitors for cancer and other diseases

Oasys Water Culminates Year with New Partnerships and Sale of World’s Largest, Most Capable Forward Osmosis System

Oasys Water Culminates Year with New Partnerships and Sale of World’s Largest, Most Capable Forward Osmosis System

December 12, 2013

Oasys Water, a world leader in innovative solutions for water treatment and desalination, today announced that they have recently signed an exclusive sales agreement with National Oilwell Varco, L.P. (NOV), a leading global provider of equipment and services used in the oil and gas market.

T2 Biosystems Strengthens Management Team as Company Prepares for Launch of Flagship T2CandidaTM Diagnostic Test

T2 Biosystems Strengthens Management Team as Company Prepares for Launch of Flagship T2CandidaTM Diagnostic Test

December 11, 2013

--Sarah Kalil Named COO; Steven Scampini as VP of Engineering--

Mascoma’s Technology Surpasses One Billion Gallons

Mascoma’s Technology Surpasses One Billion Gallons

December 11, 2013

– Mascoma’s consolidated bioprocessing (CBP) technology surpasses 1 billion gallons of ethanol produced; MGT® yeast products rapidly gain market penetration in renewable fuels market –

Agios Advances Cancer Metabolism Collaboration with Celgene

Agios Advances Cancer Metabolism Collaboration with Celgene

December 11, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 11, 2013-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced an extension of one additional year to the period of exclusivity for their strategic cancer metabolism collaboration with Celgene Corporation (NASDAQ: CELG).

Selecta Biosciences Announces Allowance of the First in a Series of Patents on the Induction of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies

Selecta Biosciences Announces Allowance of the First in a Series of Patents on the Induction of Antigen-Specific Immune Tolerance Using Selecta’s Novel Immunotherapies

December 9, 2013

Watertown, Mass. — December 9, 2013 – Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced that the US Patent and Trademark Office (USPTO) has allowed the issuance of a Selecta owned patent with the title “Tolerogenic Synthetic Nanocarriers For Inducing Regulatory B Cells”, the first in a series of patent filings on antigen-specific tolerogenic immunotherapies.

Selecta Biosciences Announces Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy

Selecta Biosciences Announces Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy

December 9, 2013

Presentation of Data at the ASH 2013 Annual Meeting

Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform

Receptos and Ono Pharmaceuticals Expand Collaboration Agreement to Include Transfer of Receptos GPCR Technology Platform

December 10, 2013

SAN DIEGO (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT) announced today that Ono has elected to amend and expand the existing collaboration agreement between the parties to include transfer to Ono of the Receptos G-protein-coupled receptor (GPCR) technology platform, a proprietary high resolution protein crystal structure determination technology which enables rational drug design for the GPCR therapeutic target class.